Abstract: Background: Major depressive disorder (MDD) is a common brain health disorder that affects at least 1 in 5 individuals in the United States (US) during their lifetime. Adults wi...
Background: Zuranolone (SAGE-217) is an investigational, neuroactive steroid and GABAA receptor positive allosteric modulator evaluated in a Phase 3 trial in patients with PPD (NCT0297832...
Background: PPD is a common medical complication during and after pregnancy. Zuranolone (SAGE-217) is an investigational neuroactive steroid and GABAA receptor positive allosteric modulat...
Abstract: Objective: WATERFALL (Phase 3; NCT04442490), adult patients with moderate to severe MDD who received zuranolone 50mg vs placebo showed statistically significant improvement in d...